Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 3908289, 19 pages
https://doi.org/10.1155/2017/3908289
Research Article

A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies

Biomonitor SAS, Villejuif Bio Park, 1 Mail du Professeur Georges Mathé, 94800 Villejuif, France

Correspondence should be addressed to Michael G. Tovey; rf.nomoib@tm

Received 23 May 2017; Revised 19 July 2017; Accepted 1 August 2017; Published 27 September 2017

Academic Editor: Douglas C. Hooper

Copyright © 2017 Christophe Lallemand et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Marcucci, M. Bellone, C. Rumio, and A. Corti, “Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells,” MAbs, vol. 5, pp. 34–46, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Rajasekaran, C. Chester, A. Yonezawa, X. Zhao, and H. E. Kohrt, “Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment,” ImmunoTargets and Therapy, vol. 4, pp. 91–100, 2015. View at Publisher · View at Google Scholar
  3. S. Chung, Y. L. Lin, C. Reed et al., “Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells,” Journal of Immunological Methods, vol. 407, pp. 63–75, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Yamashita, S. Kitano, H. Aikawa et al., “A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells,” Scientific Reports, vol. 6, p. 19772, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. B. S. Parekh, E. Berger, S. Sibley et al., “Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay,” MAbs, vol. 4, no. 3, pp. 310–318, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. Z. J. Cheng, D. Garvin, A. Paguio et al., “Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies,” Journal of Immunological Methods, vol. 414, pp. 69–81, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Aramburu, L. Azzoni, A. Rao, and B. Perussia, “Activation and expression of the nuclear factors of activated T cells, NFATp and NFATc, in human natural killer cells: regulation upon CD16 ligand binding,” The Journal of Experimental Medicine, vol. 182, no. 3, pp. 801–810, 1995. View at Google Scholar
  8. L. B. Ivashkiv, “A signal-switch hypothesis for cross-regulation of cytokine and TLR signalling pathways,” Nature Reviews Immunology, vol. 8, no. 10, pp. 816–822, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. L. B. Ivashkiv, “Cross-regulation of signaling by ITAM-associated receptors,” Nature Immunology, vol. 10, no. 4, pp. 340–347, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Pinheiro da Silva, M. Aloulou, M. Benhamou, and R. C. Monteiro, “Inhibitory ITAMs: a matter of life and death,” Trends in Immunology, vol. 29, no. 8, pp. 366–373, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Nimmerjahn and J. V. Ravetch, “Analyzing antibody-Fc-receptor interactions,” Methods in Molecular Biology, vol. 415, pp. 151–162, 2008. View at Publisher · View at Google Scholar
  12. P. Mali, L. Yang, K. M. Esvelt et al., “RNA-guided human genome engineering via Cas9,” Science, vol. 339, no. 6121, pp. 823–826, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Sakai, T. Arao, T. Shimoyama et al., “Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor,” The FASEB Journal, vol. 20, no. 2, pp. 311–313, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Kimura, K. Sakai, T. Arao, T. Shimoyama, T. Tamura, and K. Nishio, “Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor,” Cancer Science, vol. 98, no. 8, pp. 1275–1280, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. A. C. Chan and P. J. Carter, “Therapeutic antibodies for autoimmunity and inflammation,” Nature Reviews Immunology, vol. 10, no. 5, pp. 301–316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Luo, J. W. Pollard, and A. Casadevall, “Fcgamma receptor cross-linking stimulates cell proliferation of macrophages via the ERK pathway,” The Journal of Biological Chemistry, vol. 285, no. 6, pp. 4232–4242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Sun, H. Enslen, P. S. Myung, and R. A. Maurer, “Differential activation of CREB by Ca2+/calmodulin-dependent protein kinases type II and type IV involves phosphorylation of a site that negatively regulates activity,” Genes & Development, vol. 8, no. 21, pp. 2527–2539, 1994. View at Google Scholar
  18. F. Macian, “NFAT proteins: key regulators of T-cell development and function,” Nature Reviews Immunology, vol. 5, no. 6, pp. 472–484, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Furuke, P. R. Burd, J. A. Horvath-Arcidiacono, K. Hori, H. Mostowski, and E. T. Bloom, “Human NK cells express endothelial nitric oxide synthase, and nitric oxide protects them from activation-induced cell death by regulating expression of TNF-alpha,” Journal of Immunology, vol. 163, no. 3, pp. 1473–1480, 1999. View at Google Scholar
  20. G. Cartron, L. Dacheux, G. Salles et al., “Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene,” Blood, vol. 99, no. 3, pp. 754–758, 2002. View at Google Scholar
  21. D. Liu, Y. Tian, D. Sun, H. Sun, Y. Jin, and M. Dong, “The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis,” Annals of Hematology, vol. 95, no. 9, pp. 1483–1490, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Rodriguez, R. Zarate, E. Bandres et al., “Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer,” European Journal of Cancer, vol. 48, no. 12, pp. 1774–1780, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Lallemand, N. Kavrochorianou, C. Steenholdt et al., “Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists,” Journal of Immunological Methods, vol. 373, no. 1-2, pp. 229–239, 2011. View at Publisher · View at Google Scholar · View at Scopus